NCBiotech Transforms Life Sciences in North Carolina

Results from a collaborative project between Tiamat Sciences and BIOMILQ — women-owned biotechnology startups in Research Triangle Park — show the promise of using plant-based proteins to lower the cost of producing food using cultured cells.  

Astellas Pharma Inc. announced that it will acquire Propella Therapeutics, Inc., based in Pittsboro. Propella is a privately held biopharmaceutical company that has leveraged a wholly owned proprietary platform that combines medicinal chemistry with lymphatic targeting to create new oncology drugs.

Through the acquisition of Propella, Astellas will acquire PRL-02 (abiraterone decanoate), an androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer. 

Avior Bio, a small Cary startup developing a treatment for pruritus, or chronic itchy skin, has secured an agreement to license its clinical-stage therapy to a New Jersey pharmaceutical company.

Results from a collaborative project between Tiamat Sciences and BIOMILQ — women-owned biotechnology startups in Research Triangle Park — show the promise of using plant-based proteins to lower the cost of producing food using cultured cells.  

Astellas Pharma Inc. announced that it will acquire Propella Therapeutics, Inc., based in Pittsboro. Propella is a privately held biopharmaceutical company that has leveraged a wholly owned proprietary platform that combines medicinal chemistry with lymphatic targeting to create new oncology drugs.

Through the acquisition of Propella, Astellas will acquire PRL-02 (abiraterone decanoate), an androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer. 

Avior Bio, a small Cary startup developing a treatment for pruritus, or chronic itchy skin, has secured an agreement to license its clinical-stage therapy to a New Jersey pharmaceutical company.

Results from a collaborative project between Tiamat Sciences and BIOMILQ — women-owned biotechnology startups in Research Triangle Park — show the promise of using plant-based proteins to lower the cost of producing food using cultured cells.  

Astellas Pharma Inc. announced that it will acquire Propella Therapeutics, Inc., based in Pittsboro. Propella is a privately held biopharmaceutical company that has leveraged a wholly owned proprietary platform that combines medicinal chemistry with lymphatic targeting to create new oncology drugs.

Through the acquisition of Propella, Astellas will acquire PRL-02 (abiraterone decanoate), an androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer. 

Avior Bio, a small Cary startup developing a treatment for pruritus, or chronic itchy skin, has secured an agreement to license its clinical-stage therapy to a New Jersey pharmaceutical company.

Results from a collaborative project between Tiamat Sciences and BIOMILQ — women-owned biotechnology startups in Research Triangle Park — show the promise of using plant-based proteins to lower the cost of producing food using cultured cells.  

Astellas Pharma Inc. announced that it will acquire Propella Therapeutics, Inc., based in Pittsboro. Propella is a privately held biopharmaceutical company that has leveraged a wholly owned proprietary platform that combines medicinal chemistry with lymphatic targeting to create new oncology drugs.

Through the acquisition of Propella, Astellas will acquire PRL-02 (abiraterone decanoate), an androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer. 

Avior Bio, a small Cary startup developing a treatment for pruritus, or chronic itchy skin, has secured an agreement to license its clinical-stage therapy to a New Jersey pharmaceutical company.